Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

Survey of Ophthalmology

Volumn 45, Issue SUPPL. 4, 2001, Pages

  Sherwood, Mark ^a   Brandt, James ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bimatoprost; Clinical trial; Intraocular pressure; Ocular hypertension; Prostamide; Timolol

Indexed keywords

AMIDE; ANTIGLAUCOMA AGENT; BIMATOPROST; PROSTAMIDE DERIVATIVE; TIMOLOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; IRIS; MALE; MULTICENTER STUDY; OPHTHALMOSCOPY; PIGMENTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLIT LAMP; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD;

ADRENERGIC BETA-ANTAGONISTS; AMIDES; ANTIHYPERTENSIVE AGENTS; CONJUNCTIVA; DOUBLE-BLIND METHOD; EYE COLOR; FEMALE; GLAUCOMA; HUMANS; HYPEREMIA; INTRAOCULAR PRESSURE; IRIS; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; SAFETY; TIMOLOL;

EID: 0034767649     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(01)00219-3     Document Type: Article

References (17)

1. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures
2. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
3. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma
4. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial
5. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month masked, multicenter trial in the United States
6. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects
7. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial
8. The ocular pharmacology and bioavailability of AGN 192024 (Lumigan™), a novel ocular hypotensive agent
9. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma
10. A useful testing strategy in phase III trials: Combined test of superiority and test of equivalence
11. Pediatric ultrasound: A personal experience during the period 1991-1994
12. Target pressure - Glaucomatologists holey grail
13. A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure
14. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension
15. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color
16. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients
17. Target pressures in glaucoma